Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

An in vivo base editing approach targeting the PRNP gene led to a 52% increase in the lifespan of mouse models inoculated with the most common sporadic and genetic types of human pathogenic prion ...

A groundbreaking stem cell therapy offers new hope for type 1 diabetes, with early results showing potential for insulin ...

We researched over 35 mental health platforms and narrowed down 6 options for affordable online therapy. Follow our testers as they sign up and try the platforms to see if one could be a fit for you.

Christopher Groux is an editor, writer and accessibility advocate. Before joining the Forbes Health team, he covered Accessibility at Reviewed and gaming at Inverse and Newsweek. When he’s not ...

People who have this condition must take part in insulin therapy and other treatments in order to live a full and healthy life. Scientists from Uppsala University have investigated the disease ...

and a new study into genetically altered beta cell therapy tested in type 1 diabetes. We are aware of reports regarding supply issues of insulin in the UK. Some of these reports are of insuli ...